Lilly breaks ground on its $6.5 billion Houston API campus

Eli Lilly has broken ground on a $6.5 billion manufacturing campus at Generation Park, northeast of Houston, that is designated to produce small-molecule active pharmaceutical ingredients, including orforglipron, the company's oral GLP-1 drug ^[1][2]. The 236-acre site is one of several major pharmaceutical investments landing at the same business park, alongside a planned $2.3 billion Bristol Myers Squibb campus ^[2].

According to a filing with the Texas Department of Licensing and Regulation, construction on parts of the campus began in the months before the July filing, and overall completion of the full site is estimated for 2030 ^[2]. CRB Architects PC and Jacobs Engineering Group are listed as the design firms on those permitting documents ^[2]. Lilly has said the campus will create 615 new high-wage jobs, including engineers, scientists, operations staff, and lab technicians, plus roughly 4,000 construction jobs during the build-out ^[2].

Not all reporting on the project agrees on these figures. A separate account of the groundbreaking describes a 3-million-square-foot facility, 3,500 total jobs, and a 2027 completion date ^[1]. That version does not name orforglipron specifically and describes broader biopharmaceutical production lines rather than the small-molecule API focus tied to Lilly's own statements ^[1][2]. Readers should treat the 615-job, 4,000-construction-job, and 2030 completion figures from the company and the permitting filing as the more specific and sourced numbers ^[2].

The investment fits into a wider push, backed by state incentives and the Texas Jobs, Energy, Technology and Innovation program, to bring pharmaceutical manufacturing back to the United States ^[2]. U.S. Secretary of Commerce Howard Lutnick said the effort reflects "America First Trade Agenda" policy, and Texas Governor Greg Abbott said the state is working to expand biomedical manufacturing capacity ^[2]. Lilly has also received school district property tax exemptions and other state incentives tied to the project ^[2].

Why it matters for patients

Orforglipron is Lilly's oral GLP-1 medicine, notable because it is a pill rather than an injection, unlike semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) in their injectable forms. A dedicated small-molecule API plant is meant to support domestic production of the ingredient used to make that pill ^[1][2]. For patients, new manufacturing capacity in the U.S. could eventually support supply as demand for GLP-1 drugs has strained production elsewhere, though the campus will not be fully finished for years ^[2].

Because completion is not expected until around 2030, this groundbreaking does not change anything about current availability, pricing, or approval status of orforglipron or any other GLP-1 medicine ^[2]. It is also not yet known from these sources exactly when the Houston-produced ingredient would first reach the U.S. drug supply, or how much of Lilly's overall GLP-1 output it would represent.

What happens next

Construction is underway on the 236-acre site, with parts of the build reportedly starting in the months before Lilly's July permitting filing ^[2]. Overall campus completion is estimated around 2030 ^[2]. Nearby, San Jacinto College has opened a Center for Biotechnology intended to train workers for jobs at this campus and other life-sciences employers in the area, and local companies have said they plan to hire its graduates ^[2]. Bristol Myers Squibb's separate $2.3 billion campus at the same business park was announced in early August, aided by a $4.89 million state grant ^[2].